These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

610 related articles for article (PubMed ID: 28711086)

  • 1. The new paradigm of systemic therapies for metastatic melanoma.
    Volpe VO; Klufas DM; Hegde U; Grant-Kels JM
    J Am Acad Dermatol; 2017 Aug; 77(2):356-368. PubMed ID: 28711086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The future of melanoma therapy: developing new drugs and improving the use of old ones.
    Palumbo G; Di Lorenzo G; Ottaviano M; Damiano V
    Future Oncol; 2016 Nov; 12(22):2531-2534. PubMed ID: 27715206
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.
    Franken MG; Leeneman B; Gheorghe M; Uyl-de Groot CA; Haanen JBAG; van Baal PHM
    Eur J Cancer; 2019 Dec; 123():58-71. PubMed ID: 31670077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An UPLC-MS/MS method for the quantification of BRAF inhibitors (vemurafenib, dabrafenib) and MEK inhibitors (cobimetinib, trametinib, binimetinib) in human plasma. Application to treated melanoma patients.
    Rousset M; Titier K; Bouchet S; Dutriaux C; Pham-Ledard A; Prey S; Canal-Raffin M; Molimard M
    Clin Chim Acta; 2017 Jul; 470():8-13. PubMed ID: 28412197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dermatology update: The dawn of targeted treatment.
    Fernandez A
    Cleve Clin J Med; 2015 May; 82(5):309-20. PubMed ID: 25973879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controversies in the management of advanced melanoma: "gray" areas amid the "black and blue".
    Jarkowski A; Norris L; Trinh VA
    Ann Pharmacother; 2014 Nov; 48(11):1456-68. PubMed ID: 25056920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current systemic therapies for melanoma.
    Palathinkal DM; Sharma TR; Koon HB; Bordeaux JS
    Dermatol Surg; 2014 Sep; 40(9):948-63. PubMed ID: 25072125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melanocytic lesion evolution patterns with targeted therapies and immunotherapies for advanced metastatic melanoma: An observational study.
    Zhao CY; Hwang SJE; Wakade D; Carlos G; Anforth R; Fernández-Peñas P
    Australas J Dermatol; 2017 Nov; 58(4):292-298. PubMed ID: 28707403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Targeted molecular therapies (except immunotherapy)].
    Roux J; Pages C; Lebbé C
    Bull Cancer; 2014 Dec; 101 Suppl 2():S25-36. PubMed ID: 25776764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparison.
    Atkins MB; Tarhini A; Rael M; Gupte-Singh K; O'Brien E; Ritchings C; Rao S; McDermott DF
    Immunotherapy; 2019 May; 11(7):617-629. PubMed ID: 30852924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved overall survival in melanoma with combined dabrafenib and trametinib.
    Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
    N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Network Meta-Analysis of Short and Long-Term Efficacy of Targeted Therapy With Single or Double-Drug Regimens in the Treatment of Stage III/IV Malignant Melanoma Based on 16 Randomized Controlled Trials.
    Xie T; Huang CY; Kang X; Luo JS; Qin XM; Han F
    J Cell Biochem; 2018 Jan; 119(1):640-649. PubMed ID: 28628251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in the systemic treatment of metastatic melanoma.
    Yushak M; Kluger HM; Sznol M
    Oncology (Williston Park); 2013 May; 27(5):374-81. PubMed ID: 25184258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAFi/MEKi in patients with metastatic melanoma: predictive factors of complete response.
    Ribero S; Malavenda O; Fava P; Astrua C; Marra E; Osella-Abate S; Sanlorenzo M; Caliendo V; Fierro MT; Quaglino P
    Future Oncol; 2019 Jan; 15(2):133-139. PubMed ID: 30196713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Management of toxicities of BRAF inhibitors and MEK inhibitors in advanced melanoma].
    Sibaud V; Baric L; Cantagrel A; Di Palma M; Ederhy S; Paques M; Perlemuter G
    Bull Cancer; 2021 May; 108(5):528-543. PubMed ID: 33812673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors.
    Menzies AM; Wilmott JS; Drummond M; Lo S; Lyle M; Chan MM; Thompson JF; Guminski A; Carlino MS; Scolyer RA; Kefford RF; Long GV
    Cancer; 2015 Nov; 121(21):3826-35. PubMed ID: 26218930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.
    Lim SY; Menzies AM; Rizos H
    Cancer; 2017 Jun; 123(S11):2118-2129. PubMed ID: 28543695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma.
    Dika E; Patrizi A; Ribero S; Fanti PA; Starace M; Melotti B; Sperandi F; Piraccini BM
    Eur J Dermatol; 2016 Jun; 26(3):232-9. PubMed ID: 27019511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming metastatic melanoma with BRAF inhibitors.
    Hong S; Hong S; Han SB
    Arch Pharm Res; 2011 May; 34(5):699-701. PubMed ID: 21656352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.